Phase 2 Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The person had their first seizure before they were 3 months old.
- The person weighs at least 10 kilograms (approximately 22 pounds) at the time of screening.
- The person has had genetic testing done by an approved laboratory that confirmed a change (variant) in a gene called SCN2A.
- Additional criteria apply and will be reviewed by the study team.
Who may not be able to join:
- The person has a significant change in another gene (other than SCN2A) that could explain or contribute to their epilepsy or developmental condition.
- The person is currently taking more than 2 medications that work by blocking sodium channels to control seizures (confirm with trial site if unsure which medications fall into this category).
- Additional exclusion criteria apply and will be reviewed by the study team.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Praxis Precision Medicines
Phone: 617-300-8460
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation); Seizure frequency (Confirmatory Phase)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.